Ginsenoside Rg2 reduces NF-κB p65 phosphorylation, suppresses NLRP3 inflammasome activation, and decreases IL-18 and IL-1β release, thereby improving hyperglycemia, dyslipidemia, and renal dysfunction in HFD/STZ-induced diabetic mice (Li K. et al., 2025). The gene discussed is NFKB1; the disease is Hyperglycemia.